Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (27943)	2/6/1999 8:28:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

Greg, the reason I asked is that Ligand is going after approval for Targretin and other drugs for CTCL. The only reason that I can think of for targeting these "fast track" small markets is for the off label "fast track". In other words, after getting approval, all they have to show is efficacy in other applications in order to open up the world of "off label". Otherwise, why go after CTCL that has only 1000 patients per year? OTOH, I think that a lot of biotechs are doing the same thing, so Ligand isn't alone in going after "off label" markets.